Status:
COMPLETED
Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT
Lead Sponsor:
Pfizer
Conditions:
Hypertension
Eligibility:
All Genders
30-70 years
Phase:
PHASE4
Brief Summary
To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blo...
Eligibility Criteria
Inclusion
- Pt with essential hypertension who have never been treated or untreated within the previous 6 months
Exclusion
- History of Malignant Hypertension
- Sitting diastolic blood pressure \> 115mmHg or sitting Systolic blood pressure \> 200mmHg
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00147563
Start Date
October 1 2003
Last Update
April 15 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Montreal, Quebec, Canada, H2W 1R7